LRMR

Larimar Therapeutics, Inc. (LRMR) - Q3 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2025. Larimar Therapeutics is a clinical-stage biotechnology company focused on developing nomlabofusp (CTI-1601), a recombinant fusion protein designed to treat Friedreich's ataxia (FA) by delivering human frataxin (FXN) to mitochondria. The company has received Orphan Drug and Fast Track designations from the FDA and participates in the FDA's START pilot program. As of November 3, 2025, there were 85,590,392 shares of common stock outstanding.

Key Financial Metrics

Note: The company has no product revenue. Liquidity includes cash, cash equivalents, and short-term marketable securities. Restricted cash of $606,000 is excluded from the liquidity total above.

Material Changes vs. Prior Period

• Significant Increase in R&D Spend: R&D expenses for Q3 2025 increased by $31.0 million (223%) compared to Q3 2024. This was driven primarily by a $25.8 million increase in manufacturing costs for nomlabofusp, alongside increases in clinical costs, professional fees, and personnel.
• Financing Activity: In July 2025, the company completed an underwritten public offering, issuing 21,562,500 shares at $3.20 per share, raising net proceeds of approximately $65.0 million. This contrasts with the $161.8 million raised in February 2024.
• Investment Portfolio Shift: Marketable securities decreased from $150.2 million at year-end 2024 to $85.3 million at September 30, 2025, as the company utilized maturities ($150 million) to fund operations while purchasing new securities ($83.6 million).
• Cash Burn: Net cash used in operating activities for the nine months ended September 30, 2025, was $74.7 million, compared to $48.9 million in the same period in 2024.

Guidance, Outlook, and Risks

Outlook and Milestones:

• BLA Submission: The company targets submitting a Biologics License Application (BLA) seeking accelerated approval in the second quarter of 2026.
• Regulatory Update: An update on regulatory discussions and the open-label study is planned for the first quarter of 2026.
• Cash Runway: Management expects current cash, cash equivalents, and marketable securities ($175.4 million) to fund operations into the fourth quarter of 2026.

• Anaphylaxis Events: In March 2025, the Safety Monitoring Team identified anaphylaxis as an adverse drug reaction likely associated with nomlabofusp. Seven participants experienced this in the first 6 weeks of dosing. The company has implemented a modified starting dose regimen (5 mg test dose followed by 25 mg) agreed upon by the FDA to mitigate this risk.
• Surrogate Endpoint: The FDA indicated openness to considering FXN concentration as a reasonably likely surrogate endpoint (RLSE) for accelerated approval, recommending a focus on skin FXN concentrations.
• Manufacturing: The company began introducing a lyophilized product formulation (intended for commercialization) into the open-label study in July 2025.
• Going Concern: While the company currently expects to fund operations through Q4 2026, it notes that if clinical assumptions are delayed or financing is not available, it may need to reduce expenditures or seek additional capital, which could raise substantial doubt about its ability to continue as a going concern beyond that period.

Investor Verification Checklist

• Cash Runway Validation: Verify if the $175.4 million liquidity position is sufficient to cover the accelerated R&D burn rate (approx. $108M for 9 months) through Q4 2026 without further dilution.
• Anaphylaxis Mitigation: Monitor upcoming data (Q1 2026) to confirm the efficacy of the new modified dosing regimen in preventing anaphylaxis events.
• Manufacturing Costs: Scrutinize the $25.8 million quarterly increase in manufacturing costs to ensure scalability and cost-efficiency for future commercialization.
• Regulatory Pathway: Confirm the FDA's final stance on the FXN concentration surrogate endpoint and the specific safety database requirements (30 participants for 6 months, 10 for 1 year) for the BLA.
• Dilution Risk: Assess the impact of the July 2025 offering (21.5M shares) on existing shareholders and the potential need for further capital raises if the BLA timeline slips.